Does hydrochlorothiazide affect 24‑hour urinary calcium excretion?

Hydrochlorothiazide Significantly Decreases 24-Hour Urinary Calcium Excretion

Yes, hydrochlorothiazide (HCTZ) produces a hypocalciuric effect by reducing 24-hour urinary calcium excretion. This is the primary therapeutic mechanism by which thiazide diuretics prevent recurrent calcium kidney stones in patients with hypercalciuria.

Mechanism and Clinical Evidence

The 2014 AUA Kidney Stone Guidelines explicitly state that thiazide diuretics, including hydrochlorothiazide, are associated with a "hypocalciuric effect" 1. The FDA drug label confirms that hydrochlorothiazide decreases the excretion of calcium as part of its pharmacodynamic profile 2.

Magnitude of Effect

Research demonstrates consistent reductions in urinary calcium:

• A 2021 prospective randomized trial showed HCTZ 50 mg/day reduced mean 24-hour urine calcium to 220.6 ± 96.3 mg/day, with statistically significant reduction compared to pretreatment values 3

• A 1999 study found a single 50 mg dose of HCTZ acutely decreased urinary calcium excretion (U(Ca)V), calcium clearance (C(Ca)), and fractional excretion of calcium (FE(Ca)) 4

• A 1982 double-blind study demonstrated that 25 mg HCTZ twice daily produced a "distinct and continuous decrease in urinary calcium excretion" compared to placebo 5

Dose-Response Relationship

The evidence strongly supports that adequate dosing is critical for the hypocalciuric effect:

Recommended Doses for Stone Prevention

The AUA Guidelines specify thiazide dosages associated with hypocalciuric effect 1:

• Hydrochlorothiazide: 25 mg orally twice daily OR 50 mg orally once daily
• Chlorthalidone: 25 mg orally once daily
• Indapamide: 2.5 mg orally once daily

Critical Dosing Pitfall

A 2011 study revealed that only 35% of patients received the evidence-based dose of 50 mg/day HCTZ for kidney stone prevention 6. The majority received 25 mg (52%) or 12.5 mg (13%) daily—doses never studied in randomized controlled trials for stone prevention. In a subset analysis, there was a trend toward greater urinary calcium reduction when doses were increased from 25 mg to ≥50 mg/day (p = 0.051) 6.

However, a 2023 large randomized trial (NOSTONE) challenged conventional wisdom, finding no significant difference in stone recurrence among patients receiving HCTZ 12.5 mg, 25 mg, 50 mg, or placebo once daily over a median 2.9 years 7. This contradicts earlier evidence and raises questions about once-daily dosing efficacy.

Timing and Duration of Effect

A 2025 study comparing 12-hour urine collections found that:

• Chlorthalidone (CTD) 25 mg reduced urinary calcium for both 12-hour periods regardless of morning or evening administration (baseline 130 ± 70 mg/g Cr reduced to 76 ± 52 mg/g Cr with morning dosing, p < 0.02) 8
• HCTZ 25 mg once daily did NOT significantly reduce urinary calcium regardless of administration time 8

This suggests chlorthalidone is superior to hydrochlorothiazide for stone prevention due to its longer duration of action 8.

Maximizing the Hypocalciuric Effect

To optimize urinary calcium reduction, the AUA Guidelines emphasize 1:

• Dietary sodium restriction must be continued when thiazides are prescribed to maximize the hypocalciuric effect and limit potassium wasting
• Potassium supplementation (either potassium citrate or chloride) may be needed during thiazide therapy
• The combination enhances efficacy: sodium restriction alone increases calcium excretion, which counteracts thiazide effects

Important Caveats

Metabolic Side Effects

The FDA label warns that metabolic toxicities associated with excessive electrolyte changes are dose-related 2. Common adverse effects include:

• Hypokalemia (monitor closely, especially with higher doses)
• Hyponatremia
• Hyperglycemia and new-onset diabetes
• Hyperuricemia and gout
• Hypomagnesemia (HCTZ increases fractional excretion of magnesium while decreasing calcium excretion) 4

The 2023 NOSTONE trial confirmed these risks were more common with HCTZ than placebo 7.

Serum Calcium Changes

While urinary calcium decreases, serum total calcium and ionized calcium (Ca2+) concentrations increase 4, 5. This is a compensatory response and should be monitored.

Special Populations

In children with Dent disease, HCTZ doses >0.4 mg/kg/day decreased calcium excretion but were associated with significant adverse events including muscle cramps, hypovolemia, hypokalemia, and hyponatremia 9. Thiazide therapy should be used cautiously in pediatric populations.

Clinical Application Algorithm

For patients with recurrent calcium stones and hypercalciuria:

1. Confirm hypercalciuria on 24-hour urine collection (typically >200-250 mg/day)

2. Initiate dietary modifications first:

   • Sodium restriction to <2,300 mg/day
   • Adequate fluid intake (goal urine volume >2.5 L/day)
   • Normal calcium intake (1,000-1,200 mg/day)

3. If hypercalciuria persists, add thiazide diuretic:

   • Preferred: Chlorthalidone 25 mg once daily (longer acting, more effective) 8
   • Alternative: Hydrochlorothiazide 25 mg twice daily or 50 mg once daily 1
   • Note: Once-daily HCTZ may be less effective 8, 7

4. Monitor within 4 weeks of initiation:

   • Serum potassium, sodium, calcium
   • Serum creatinine
   • Consider 24-hour urine calcium to confirm response

5. Add potassium citrate if:

   • Hypokalemia develops
   • Hypocitraturia is present (synergistic stone prevention benefit)

6. Continue sodium restriction to maximize hypocalciuric effect

The bottom line: Hydrochlorothiazide definitively reduces 24-hour urinary calcium excretion through its hypocalciuric effect, but adequate dosing (≥50 mg/day or 25 mg twice daily), sodium restriction, and potassium monitoring are essential for efficacy and safety. Chlorthalidone may be a superior alternative.